Oldenburg, Johannes
Chambost, Herve
Liu, Hai
Hawes, Charles
You, Xiaojun
Yang, Xinqun
Newman, Vanessa
Robinson, Tara M.
Hatswell, Anthony J.
Hinds, David
Santos, Sandra
Ozelo, Margareth
Clinical trials referenced in this document:
Documents that mention this clinical trial
Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
https://doi.org/10.1007/s12325-024-02834-9
Funding for this research was provided by:
BioMarin Pharmaceutical
Universitätsklinikum Bonn
Article History
Received: 11 August 2023
Accepted: 5 March 2024
First Online: 15 April 2024
Declarations
:
: Johannes Oldenburg received reimbursement for attending symposia/congresses, honoraria for speaking or consulting, or funds for research from Bayer, Biogen Idec, Biotest, Chugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, and Sobi. Herve Chambost received consulting payments from BioMarin Pharmaceutical Inc., CSL Behring, LFB, Novo Nordisk, Pfizer, Roche Chugai, and Sobi; received speaker fees from BioMarin Pharmaceutical Inc., CSL Behring, Pfizer, Roche, and Sobi; and received travel support from BioMarin Pharmaceutical Inc., CSL Behring, Novo Nordisk, Octapharma, Roche, and Sobi. Anthony J. Hatswell is an employee of Delta Hat Ltd, who were contracted by BioMarin Pharmaceutical Inc. to contribute to these analyses. Hai Liu, Xinqun Yang, Tara M. Robinson, and David Hinds are employees and stockholders of BioMarin Pharmaceutical Inc. Charles Hawes and Sandra Santos are employees and stockholders of BioMarin UK Ltd. Vanessa Newman was an employee of BioMarin Pharmaceutical Inc., at the time of study and is now the current owner of Garthorne Medical & Clinical Limited. Xiaojun You was an employee of BioMarin Pharmaceutical Inc., at the time of study and is a current employee of Regeneron. Margareth Ozelo reports consulting fees from Bayer, BioMarin Pharmaceutical Inc., Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda; research grants from Pfizer, Roche, and Takeda; participation as a clinical trial investigator for BioMarin Pharmaceutical Inc., Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda; speaker honoraria from Bayer, BioMarin Pharmaceutical Inc., Novo Nordisk, Roche, and Takeda; travel support from Novo Nordisk, Roche, and Takeda; and participation in grant reviewing for Grifols.
: This manuscript provides a post hoc analysis of previously conducted studies and does not include the addition of new studies with human participants or animal subjects. As previously reported, the 270-902 and GENEr8-1 protocols were approved by the institutional review boards or independent ethics committees of all participating sites, and all participants provided written informed consent. Both trials were performed in accordance with the ethical principles set forth by the Declaration of Helsinki.